UK markets close in 3 hours 46 minutes
  • FTSE 100

    7,105.47
    -63.21 (-0.88%)
     
  • FTSE 250

    22,679.91
    -232.82 (-1.02%)
     
  • AIM

    1,189.63
    -6.42 (-0.54%)
     
  • GBP/EUR

    1.1741
    +0.0016 (+0.14%)
     
  • GBP/USD

    1.3322
    +0.0044 (+0.33%)
     
  • BTC-GBP

    42,372.97
    -793.48 (-1.84%)
     
  • CMC Crypto 200

    1,441.69
    -27.39 (-1.86%)
     
  • S&P 500

    4,513.04
    -53.96 (-1.18%)
     
  • DOW

    34,022.04
    -461.68 (-1.34%)
     
  • CRUDE OIL

    65.84
    +0.27 (+0.41%)
     
  • GOLD FUTURES

    1,779.40
    -4.90 (-0.27%)
     
  • NIKKEI 225

    27,753.37
    -182.25 (-0.65%)
     
  • HANG SENG

    23,788.93
    +130.01 (+0.55%)
     
  • DAX

    15,229.56
    -243.11 (-1.57%)
     
  • CAC 40

    6,793.36
    -88.51 (-1.29%)
     

The Worldwide Lung Injury Industry is Expected to Reach $2+ Billion by 2030

·7-min read

Dublin, Nov. 05, 2021 (GLOBE NEWSWIRE) -- The "Lung injury Market by Therapy, Injury Type, and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

The global lung injury market was valued at $1,579.47 in 2020, and is projected to reach $2,417.41 by 2030 registering a CAGR of 4.20% from 2021 to 2030.

Lung injury is a disorder of acute inflammation that causes disruption of the lung endothelial and epithelial barriers. Often it becomes a life-threatening condition caused by severe acute hypoxemic respiratory failure. In addition, it is a key reason of mortality and morbidity in critically ill patients without any evidence of hydrostatic pulmonary edema. Symptoms observed in acute lung injury include severe shortness of breath, low blood pressure, confusion, and extreme tiredness. This type of injury has a significant impact on public health, with high incidence rate across the world. Moreover, it requires administration of rapid and goal-oriented therapy to prevent further lung damage.

The growth of the global lung injury market is majorly driven by rise in prevalence of lung-related diseases and increase in geriatric population. Furthermore, increase in awareness related to treatment of acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) is expected to notably contribute toward the growth of the global market. However, complications associated with the use of therapies and low adoption rate due to these complications hinder the market growth. On the contrary, pipeline drugs for the treatment of acute lung injury are being studied in late phase of clinical trials. . These drugs are likely to be available in the market in next few years, which is expected to offer remunerative opportunity for the expansion of the market during the forecast period.

The global lung injury market is segmented into therapy, injury type, end user, and region. Depending on therapy, the market is bifurcated into medication and devices. The medication segment is further categorized into pharmacotherapy, fluid management, and inhaled nitric oxide. Moreover, the devices is subdivided into mechanical ventilation and adjunctive procedures devices. On the basis of injury type, the market is segregated into direct injury and indirect injury. By end user, it is fragmented into hospitals & clinics, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

  • The study provides an in-depth analysis of the global lung injury market along with the current trends and future estimations to elucidate the imminent investment pockets.

  • A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.

  • Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.

  • Extensive analysis of the key segments of the industry helps understand the applications and products of lung injury used across the globe.

  • Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

Key Topics Covered:

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET LANDSCAPE
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter's five force analysis
3.4. Top player positioning, 2020
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Rise in prevalence of lung-related diseases
3.5.1.2. Surge in geriatric population
3.5.1.3. Increase in adoption of new technologies with availability of high number of drugs used in lung injury treatment
3.5.1.4. Recent advancements in research related to treatment of acute lung injury
3.5.2. Restraint
3.5.2.1. High cost of therapies coupled with lack of established treatment
3.5.3. Opportunity
3.5.3.1. New developments in therapies
3.5.4. Impact analysis
3.6. COVID-19 impact analysis on the lung injury market

CHAPTER 4: LUNG INJURY MARKET, BY THERAPY
4.1. Overview
4.1.1. Market size and forecast
4.2. Medication
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.2.4. Market size and forecast, by type
4.2.4.1. Pharmacotherapy
4.2.4.1.1. Market size and forecast
4.2.4.1.2. Lung injury pharmacotherapy market size and forecast, by region
4.2.4.1.3. Lung injury pharmacotherapy market size and forecast, by country
4.2.4.2. Fluid management
4.2.4.2.1. Market size and forecast
4.2.4.2.2. Lung injury fluid management market size and forecast, by region
4.2.4.2.3. Lung injury fluid management market size and forecast, by country
4.2.4.3. Inhaled nitric oxide
4.2.4.3.1. Market size and forecast
4.2.4.3.2. Lung injury inhaled nitric oxide market size and forecast, by region
4.2.4.3.3. Lung injury Inhaled nitric oxide market size and forecast, by country
4.3. Devices
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.3.4. Market size and forecast, by type
4.3.4.1. Mechanical ventilation
4.3.4.1.1. Market size and forecast
4.3.4.1.2. Lung injury mechanical ventilation market size and forecast, by region
4.3.4.1.3. Lung injury mechanical ventilation market size and forecast, by country
4.3.4.2. Adjunctive procedures devices
4.3.4.2.1. Market size and forecast
4.3.4.2.2. Lung injury adjunctive procedures devices market size and forecast, by region
4.3.4.2.3. Lung injury adjunctive procedures devices market size and forecast, by country

CHAPTER 5: LUNG INJURY MARKET, BY INURY TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Direct injury
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Indirect injury
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

CHAPTER 6: LUNG INJURY MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals & clinics
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Others
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country

CHAPTER 7: LUNG INJURY MARKET, BY REGION

CHAPTER 8: COMPANY PROFILES
8.1. APEPTICO FORSCHUNG UND ENTWICKLUNG GMBH
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Key strategic moves and developments
8.2. BAYER AG
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. GENERAL ELECTRIC COMPANY
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. GLAXOSMITHKLINE PLC.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.5. KONINKLIJKE PHILIPS N. V
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. LINDE PLC
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. MEDTRONIC PLC.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. ONY BIOTECH INC.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.9. PFIZER INC.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.10. TEVA PHARMACEUTICAL INDUSTRIES LTD.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance

For more information about this report visit https://www.researchandmarkets.com/r/49n9gy

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting